
Hoka Vs. On Cloud: Experts Help Us Break Down These Top Shoe Brands
Both Hoka and On Cloud shoes are known for their unique sole designs. Illustration: Forbes / Photo: Retailers
In many ways, the similarities between these brands can make it challenging to choose one over the other. But there exists just enough differences that it's likely you'll end up preferring one based on your body and your favorite activities. So, which is the better choice for you when the question is Hoka vs. On Cloud? Let's take a closer look to find out.
As we've established, both Hoka and On Cloud are relatively new and unique running brands.
Hoka was founded in the French Alps, where trail running influenced its footwear. The brand's thick soles were designed to absorb repetitive impact, with an emphasis on support and cushioning over unstable terrain. Today, the brand's roster includes not only trail shoes, but road shoes, walking shoes, hiking shoes and so much more. Some styles still embrace the brand's thick, signature cushioning; others are slim, light and built for speed.
On Cloud was founded in 2010 by three Swiss friends who sought to create a road shoe that delivered soft landings and a firm takeoff. Runners at the time were a bit skeptical given the unique styling of On's first shoe, but it didn't take long for the design to receive the ISPO Brandnew Award, which recognizes groundbreaking products. Months later, On shoes were sitting on store shelves, and the rest, as they say, is history.
Before we move on, let's clear up a couple of things. When Hoka was founded, the company was called Hoka One One, which many people pronounced as 'won won.' In reality, it was meant to be pronounced 'Own-Ey Own-Ey,' as the name comes from the Māori language and means 'fly over the earth.' In late 2021, the brand shortened its name to simply Hoka.
As for On Cloud, the company isn't actually called On Cloud—it's just On. But its Cloud line of shoes became so popular that the name On Cloud unofficially stuck. To keep things simple (and avoid confusion), we're rolling with it throughout this guide. Or running with it, if you will.
On Cloud shoes feature pods that lack material for better rebound On Hoka Vs. On Cloud: Cushioning
When it comes to the cushioning, Hoka reigns supreme. Its shoes were designed with trail running in mind, so best-selling styles feature grippy outsoles and chunky midsoles. This design once looked odd, but it's quite common in the running world nowadays.
Most pairs of Hokas are maximally cushioned due to a thick layer of compression-molded EVA foam that compresses on impact and helps propel you forward with each step. 'The shock absorption feature lessens the stress on muscles and joints,' explains Dr. Daniel Cuttica, a board certified orthopaedic surgeon with The Centers for Advanced Orthopaedics. 'They are beneficial for those suffering from various foot and ankle conditions, such as plantar fasciitis and arthritis.'
Ironically, On Cloud's cushioning comes primarily from a lack of cushioning, or empty space: The CloudTec cutouts in the soles of its shoes allow for impact absorption. When partnered with the foam material used to create them, the reduction is ample, albeit not as significant as you get with Hokas. But the pods do provide excellent propulsion as they regain their shape after each step. Hoka Vs. On Cloud: Stability
"Stability' primarily refers to how a shoe supports your foot. Some shoes are specifically designed to prevent your foot from rolling inward as you step, which is known as overpronation. Pronating can lead to foot, ankle, knee and even hip and spine issues, so it's important to correct it, if it's a problem.
As it happens, both Hoka and On Cloud make shoes with stability features. Hoka adds stability through the use of a 'J-Frame,' which is a band of thicker, denser foam that wraps around the heel and underfoot on the inside of the shoe. Similarly, On Cloud shoes add stability by using thicker and firmer CloudTec pods in the same place. These designs provide extra support to ensure your foot doesn't roll as you step.
If you're looking for a true stability shoe, the Hoka Arahi 8 is a great option thanks to its 'J-Frame' underfoot support, while the On Cloudflyer 5 uses dual-density foam to create a similarly supportive experience.
Balance is also an important element of stability. 'Hoka has a higher stack height than On Cloud, which helps with the plush maximalist design but also makes one higher from the ground,' explains Dr. Samantha Landau, a faculty member at New York College of Podiatric Medicine. 'Some people find the shoes have reduced proprioception or 'feel' for the ground as they run,' so if balance is an issue for you, On Clouds may be the better choice. Hoka Vs. On Cloud: Durability
Both Hoka and On Cloud shoes are highly durable, often surpassing the 300-mile mark that you should expect—at a minimum—from a good pair of running shoes. That said, the unique soles of each brand's shoes will begin to break down not long after that point.
With Hoka shoes, wear and tear may be harder to spot due to the thick, cushioned soles. But if you notice your feet start rolling inward more than they used to, or if the foam feels a bit flat, it's likely time for a new pair.
On Cloud shoes tend to show their age more visibly. The CloudTec pods may lose their shape, and that signature springy sensation in the midsole will fade. And if the tread has worn down to the point where you can see the foam underneath, it's well past time to replace them.
Miles of running on hard surfaces can take a toll on the soft foam of Hoka midsoles. Hoka Hoka Vs. Brooks: Price
Price isn't going to be a decisive factor when choosing between Hoka and On Cloud. Look through Hoka's lineup and you'll find that popular styles range from $100 to $200. The Clifton 10, for example, is $145, while the Bondi 9 is $175. As for On Cloud, prices are similar. The Cloud 6 is $160, and the Cloudmonster, $170.
As tempting as it may be to shop for a cheap shoe, consider comfort, use case and style instead. Shoes sell for similar enough prices across both brands that it's hardly worth trying to save money by choosing one over the other for that reason alone. Hoka Vs. Brooks: Which Is Right For You?
'Since they are tackling essentially different issues, Hoka and On are not competing for the same runner,' says Dr. Jodi Schoenhaus, DPM with the Foot, Ankle and Leg Vein Center. 'Hoka provides treatment for a variety of ailments, including plantar fasciitis, sore knees and just spending too much time on harsh flooring.'
In aiming to maximize comfort, the designs include wide-fit alternatives, high-stack midsoles and structured support. 'Comfort isn't a luxury; it's the main objective," Schoenhaus notes. "This explains why Hoka rules hospital halls and recovery runs alike. It's a brand designed to increase endurance and absorb impact.'
On Cloud shoes, on the other hand, 'combine elegance and performance with precision,' explains Schoenhaus. 'The Speedboard plate and CloudTec pods sharpen the ride rather than make it softer. Every component of the design functions as propulsion, transforming it from a running shoe into a performance item that blends in perfectly with city life.'
On Cloud shoes were designed with a fast-paced, fashion-forward athlete in mind—someone who demands the same level of performance from their equipment on the road as they do on the track, or when simply strolling down 5th Avenue.
Long story short: Hokas are a great choice for more cushioning and support, especially if you stand on your feet all day, or have conditions like plantar fasciitis. And if you're looking for trendy styles that look good and perform, On Cloud shoes should meet your needs. Why Trust Forbes Vetted
The gear review team at Forbes Vetted has tested, researched and reviewed a wide range of footwear options over the years, including everything from technical sandals to walking shoes to hunting boots . This piece was written by Steven John , a staff writer with Forbes Vetted who runs multiple times a week, on roads, trails and treadmills, and who has tested dozens of pairs of road and trail running shoes over the years.
, a staff writer with Forbes Vetted who runs multiple times a week, on roads, trails and treadmills, and who has tested dozens of pairs of road and trail running shoes over the years. The story was edited by Forbes Vetted gear editor Cam Vigliotta who has extensive experience testing gear and apparel, including footwear. His recent reviews include the Hoka Clifton 10 and Brooks Ghost 17.
who has extensive experience testing gear and apparel, including footwear. His recent reviews include the Hoka Clifton 10 and Brooks Ghost 17. John spoke to several experts for this piece, including: Dr. Jodi Schoenhaus, DPM with the Foot, Ankle & Leg Vein Center; Dr. Samantha Landau, a faculty member at New York College of Podiatric Medicine; and Dr. Daniel J. Cuttica, a board certified orthopaedic surgeon with The Centers for Advanced Orthopaedics.
Both Hoka and On Cloud regularly launch new and updated shoes, so we will periodically revisit and update this piece to be sure it contains accurate and relevant product information. It was first published in July 2025.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Ashmore Group (LON:ASHM) investors are sitting on a loss of 39% if they invested five years ago
Ashmore Group Plc (LON:ASHM) shareholders will doubtless be very grateful to see the share price up 33% in the last quarter. But if you look at the last five years the returns have not been good. In fact, the share price is down 58%, which falls well short of the return you could get by buying an index fund. It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. During the five years over which the share price declined, Ashmore Group's earnings per share (EPS) dropped by 19% each year. The share price decline of 16% per year isn't as bad as the EPS decline. The relatively muted share price reaction might be because the market expects the business to turn around. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). Dive deeper into Ashmore Group's key metrics by checking this interactive graph of Ashmore Group's earnings, revenue and cash flow. What About Dividends? It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Ashmore Group, it has a TSR of -39% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return. A Different Perspective Ashmore Group provided a TSR of 11% over the year (including dividends). That's fairly close to the broader market return. The silver lining is that the share price is up in the short term, which flies in the face of the annualised loss of 7% over the last five years. We're pretty skeptical of turnaround stories, but it's good to see the recent share price recovery. It's always interesting to track share price performance over the longer term. But to understand Ashmore Group better, we need to consider many other factors. Case in point: We've spotted 3 warning signs for Ashmore Group you should be aware of, and 2 of them make us uncomfortable. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on British exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
19 minutes ago
- Yahoo
PHSC Full Year 2025 Earnings: UK£0.012 loss per share (vs UK£0.022 profit in FY 2024)
PHSC (LON:PHSC) Full Year 2025 Results Key Financial Results Revenue: UK£3.22m (down 15% from FY 2024). Net loss: UK£126.2k (down by 151% from UK£248.8k profit in FY 2024). UK£0.012 loss per share (down from UK£0.022 profit in FY 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period PHSC shares are down 14% from a week ago. Risk Analysis It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with PHSC (at least 1 which is a bit unpleasant), and understanding these should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
Carl Zeiss Meditec (ETR:AFX) shareholders have endured a 62% loss from investing in the stock three years ago
If you love investing in stocks you're bound to buy some losers. Long term Carl Zeiss Meditec AG (ETR:AFX) shareholders know that all too well, since the share price is down considerably over three years. Sadly for them, the share price is down 63% in that time. Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During the three years that the share price fell, Carl Zeiss Meditec's earnings per share (EPS) dropped by 16% each year. This reduction in EPS is slower than the 28% annual reduction in the share price. So it seems the market was too confident about the business, in the past. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here. A Different Perspective While the broader market gained around 23% in the last year, Carl Zeiss Meditec shareholders lost 16% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 7% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Carl Zeiss Meditec better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Carl Zeiss Meditec , and understanding them should be part of your investment process. For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on German exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio